glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-18. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
== Awards and honours == 2004 CWA Ian Fleming Steel Dagger Award shortlist for Dead I Well May Be 2007 Audie Award for Best Thriller/Suspense for The Dead Yard. 2008 Young Hoosier Award and Beehive Award shortlist for The Lighthouse Land 2009 World Book Day Award longlist for The Bloomsday Dead 2010 Spinetingler Award for Best Novel for Fifty Grand 2011 Theakston Old Peculier Crime Novel of the Year Award longlist for Fifty Grand 2013 Spinetingler Award for Best Crime Novel for The Cold Cold Ground 2013 Prix Du Meilleur Polar shortlist for The Cold Cold Ground 2013 Crime Fest Last Laugh Award shortlist for The Cold Cold Ground 2013 Ned Kelly Award for Best Crime Novel shortlist for I Hear the Sirens in the Street 2014 Barry Award (for crime novels)for Best Mystery Novel (Paperback Original) for I Hear the Sirens in the Street 2014 Grand Prix de Littérature Policière shortlist for I Hear the Sirens in the Street 2014 Theakston Old Peculier Crime Novel of the Year Award shortlist for I Hear the Sirens in the Street 2014 Ned Kelly Award for Best Fiction for In the Morning I'll Be Gone 2015 Audie Award For Best Thriller shortlist for In the Morning I'll Be Gone 2015 Prix SNCF Du Polar shortlist for The Cold Cold Ground 2015 Ned Kelly Award shortlist for Gun Street Girl 2015 Boston Globe Best Book of 2015 for Gun Street Girl 2015 Irish Times Best Crime Novel of 2015 for Gun Street Girl 2016 Edgar Award (Best Paperback Original) shortlist for Gun Street Girl 2016 Anthony Award (Best Paperback Original) shortlist for Gun Street Girl 2016 Audie Award for Best Mystery shortlist for Gun Street Girl 2016 Boston Globe Best Book of 2016 for Rain Dogs 2016 Irish Times Best Crime Novel of 2016 for Rain Dogs 2016 Theakston Old Peculier Crime Novel of the Year Award shortlist for Rain Dogs 2016 Ned Kelly Award shortlist for Rain Dogs 2016 CWA Ian Fleming Steel Dagger shortlist for Rain Dogs 2017 Edgar Award (Best Paperback Original) for Rain Dogs 2017 Barry Award for Rain Dogs 2017 Anthony Award (Best Paperback Original) for Rain Dogs 2017 Ned Kelly Award for Police at the Station and They Don't Look Friendly 2017 CWA Ian Fleming Steel Dagger Award shortlist for Police at the Station and They Don't Look Friendly 2017 Boston Globe Best Book of 2017 for Police at the Station and They Don't Look Friendly 2018 International Thriller Writers Awards (Best Paperback Original Novel) shortlist for Police at the Station and They Don't Look Friendly 2019 Time magazine Books of the Year for The Chain 2020 Theakston's Old Peculier Crime Novel of the Year Award 2020 winner for The Chain. 2020 Ian Fleming Steel Dagger Award longlist for The Chain; CWA Body in the Library longlist for The Chain 2020 International Thriller Writers Award for Best Hardcover Novel, The Chain. 2020 Ned Kelly Award for Best International Crime Fiction for The Chain. 2020 Macavity Awards for Best Mystery Novel by Mystery Readers International for The Chain. 2020 Barry Award (for crime novels) for Best Mystery Novel winner for The Chain. 2022 In The Morning I'll Be Gone winner of the Prix Polar Pourpres for Best Mystery Novel 2022 Best Thrillers of 2022 for The Island. New York Times 2023 Best Thrillers of 2023 for The Detective Up Late. Washington Post 2024 Barry Award (for crime novels) nominee for Best Mystery Novel for The Detective Up Late
The yeast genus Saccharomyces (sugar mold) is favored for winemaking (for both grapes as well as other fruit wines in addition to being used in brewing and breadmaking) because of the generally reliable and positive attributes it can bring to the wine. These yeasts will usually readily ferment glucose, sucrose and raffinose and metabolize glucose, sucrose, raffinose, maltose and ethanol. However, Saccharomyces cannot ferment or utilize pentoses (such as arabinose) which is usually present in small amount in wines as residual sugars. In addition to Saccharomyces cerevisiae, other species within the genus Saccharomyces that are involved with winemaking include:
Rumbold had a meeting with the Polish Minister for Foreign Affairs, Stanisław Patek, who declared that he was disappointed with his people's behaviour and "spoke strongly about the tactlessness and rigidity of the Polish Military authorities". On 10 March, Beaumont wrote of numerous continuing difficulties being made by Polish officials and stressed the "ill-will between Polish and German nationalities and the irritation due to Polish intolerance towards the German inhabitants in the Corridor (now under their rule), far worse than any former German intolerance of the Poles, are growing to such an extent that it is impossible to believe the present settlement (borders) can have any chance of being permanent...". The Poles began to harden their position, and Rumbold reported to Curzon on 22 March 1920 that Count Stefan Przeździecki, an official of the Polish Foreign Office, had told Sir Percy Loraine, First Secretary at the legation at Warsaw, that the Poles questioned the impartiality of the Inter-Allied Commissions and indicated that the Polish government might refuse to recognise the results of the plebiscites. Infiltration attempts of Polish irregulars into the Marienwerder area were checked by Italian troops.
replication eye Also replication bubble. The eye-shaped structure that forms when a pair of replication forks, each growing away from the origin, separates the strands of the double helix during DNA replication.
Sources: en.wikipedia.org
The Cossacks are a predominantly East Slavic, Eastern Orthodox Christian militant people, originating from the Pontic–Caspian steppe of eastern Ukraine and southern Russia. Cossacks played an important role in defending the southern borders of the Polish-Lithuanian Commonwealth and of the Russian Empire, countering the Crimean–Nogai raids, alongside economically developing steppe regions north of the Black Sea and around the Azov Sea. Historically, they were a semi-nomadic and semi-militarized people, who were allowed a great degree of self-governance in exchange for military service under the nominal suzerainty of various Eastern European states. Although numerous ethnic, linguistic and religious groups came together to form the Cossacks, the East Slavs predominated, with other groups gradually coalesced and Slavicized, thereby adopting East Slavic culture, East Slavic languages and Eastern Orthodox Christianity. The rulers of the Polish–Lithuanian Commonwealth and Russian Empire endowed Cossacks with certain special privileges in return for the military duty to serve in the irregular troops: Zaporozhian Cossacks were mostly infantry soldiers, using war wagons, while Don Cossacks were primarily cavalry soldiers. The various Cossack groups organized along military lines, with large autonomous groups called hosts. Each host was responsible for protecting a territory consisting of affiliated villages called stanitsas.
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a coronavirus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic that began in late 2019. The virus previously had the provisional name 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019 (HCoV-19 or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization designated the outbreak a public health emergency of international concern from January 30, 2020, to May 5, 2023. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans. SARS‑CoV‑2 is a virus of the species Betacoronavirus pandemicum (SARSr-CoV), as is SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak. Some animal-borne coronaviruses are more closely related to SARS-CoV-2 than SARS-CoV-1 is. The closest known relative is the BANAL-52 bat coronavirus. SARS-CoV-2 is of zoonotic origin; its close genetic similarity to bat coronaviruses suggests it emerged from such a bat-borne virus. Research is ongoing as to whether SARS‑CoV‑2 came directly from bats or indirectly through any intermediate hosts. The virus shows little genetic diversity, indicating that the spillover event introducing SARS‑CoV‑2 to humans is likely to have occurred in late 2019. Epidemiological studies estimate that in the period between December 2019 and September 2020 each infection resulted in an average of 2.4–3.4 new infections when no members of the community were immune and no preventive measures were taken.
=== Preterm Labor === The BSCI compound called 'BN83470' in pregnant mice averted infection-induced preterm birth (PTB) by blocking various inflammatory pathways in the uterus and preventing the infiltration of immune cells into the uterine myometrium. In a nonhuman primate model of Group B Streptococcus (GBS)-induced preterm labour, another BSCI compound called 'FX125L' was able to inhibit preterm labour and suppress the cytokine response. No antibiotics were administered during these experiments, allowing the GBS infection to progress and invade the amniotic cavity and the fetus. Despite the invasive GBS infection, prophylactic BSCI treatment significantly reduced the levels of cytokines in the amniotic fluid, fetal plasma, lung, and brain, indicating its ability to suppress the inflammatory response. Current animal studies have not shown any significant fetal toxicity associated with BSCI compounds. However, further research, particularly through human pre-clinical trials, is now underway to understand the impact of BSCIs on the fetal immune response and development.
=== Host immune response === Epithelial cells express many genes that encode immune mediators and proteins involved in cell-cell communication with hematopoietic immune cells. The resulting immune functions of these non-hematopoietic, structural cells contribute to the mammalian immune system ("structural immunity"). Relevant aspects of the epithelial cell response to infections are encoded in the epigenome of these cells, which enables a rapid response to immunological challenges.
== Bibliography == Greenwood, Norman N.; Earnshaw, Alan (1997). Chemistry of the Elements (2nd ed.). Butterworth–Heinemann. ISBN 978-0080379418. Haire, Richard G. (2006). "Einsteinium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 1577–1620. doi:10.1007/1-4020-3598-5_12. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on 2010-07-17. Holleman, Arnold F. & Wiberg, Nils (2007). Textbook of Inorganic Chemistry (102nd ed.). Berlin: de Gruyter. ISBN 978-3-11-017770-1. Seaborg, G.T., ed. (23 January 1978). Proceedings of the Symposium Commemorating the 25th Anniversary of Elements 99 and 100 (PDF). Report LBL-7701.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.